UK markets open in 6 hours 40 minutes

Inhibikase Therapeutics, Inc. (IKT)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.5800+0.2100 (+15.33%)
At close: 04:00PM EDT
1.5799 -0.00 (-0.01%)
After hours: 06:26PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 8.87M
Enterprise value -4.14M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)0.81
Enterprise value/revenue N/A
Enterprise value/EBITDA 0.21

Trading information

Stock price history

Beta (5Y monthly) 1.20
52-week change 3-61.75%
S&P500 52-week change 323.06%
52-week high 34.3500
52-week low 30.7900
50-day moving average 32.2210
200-day moving average 31.8269

Share statistics

Avg vol (3-month) 3139.82k
Avg vol (10-day) 363.59k
Shares outstanding 56.48M
Implied shares outstanding 66.57M
Float 85.57M
% held by insiders 113.85%
% held by institutions 19.58%
Shares short (28 Mar 2024) 420.28k
Short ratio (28 Mar 2024) 40.38
Short % of float (28 Mar 2024) 40.36%
Short % of shares outstanding (28 Mar 2024) 40.31%
Shares short (prior month 29 Feb 2024) 451.34k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:6
Last split date 330 Jun 2023

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023


Profit margin 0.00%
Operating margin (ttm)-440,356,600.00%

Management effectiveness

Return on assets (ttm)-63.67%
Return on equity (ttm)-118.88%

Income statement

Revenue (ttm)260.5k
Revenue per share (ttm)0.05
Quarterly revenue growth (yoy)-100.00%
Gross profit (ttm)N/A
EBITDA -19.91M
Net income avi to common (ttm)-19.03M
Diluted EPS (ttm)-3.5700
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)13.25M
Total cash per share (mrq)2.05
Total debt (mrq)622k
Total debt/equity (mrq)5.67%
Current ratio (mrq)4.13
Book value per share (mrq)1.77

Cash flow statement

Operating cash flow (ttm)-18.09M
Levered free cash flow (ttm)-12.17M